Tiotropium & olodaterol — Competitive Intelligence Brief

Tiotropium & olodaterol (Tiotropium & olodaterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory / Pulmonology.

marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule

Target snapshot

Tiotropium & olodaterol (Tiotropium & olodaterol) — University of Dundee. Tiotropium and olodaterol is a combination of a long-acting muscarinic antagonist and a long-acting beta-2 agonist that work together to relax and open airways in the lungs.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tiotropium & olodaterol TARGET	Tiotropium & olodaterol	University of Dundee	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
UMEC/VI	UMEC/VI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
GSK 573719 +GW642444 125/25	GSK 573719 +GW642444 125/25	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; Beta-2 adrenergic receptor
Glycopyrronium/Formoterol Fumarate	Glycopyrronium/Formoterol Fumarate	AstraZeneca	phase 3	LAMA/LABA combination (Long-Acting Muscarinic Antagonist / Long-Acting Beta-2 Agonist)	Muscarinic M3 receptor; Beta-2 adrenergic receptor
GSK573719/VI 62.5/25	GSK573719/VI 62.5/25	GlaxoSmithKline	phase 3	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor; beta-2 adrenergic receptor
Revefenacin 175 µg, Formoterol 20 µg	Revefenacin 175 µg, Formoterol 20 µg	University of Tennessee Graduate School of Medicine	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor; beta-2 adrenergic receptor
UMEC/VI DPI	UMEC/VI DPI	GlaxoSmithKline	marketed	Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA)	Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) class)

1. GlaxoSmithKline · 5 drugs in this class
2. University of Dundee · 2 drugs in this class
3. National Institute of Respiratory Diseases, Mexico · 1 drug in this class
4. University of Tennessee Graduate School of Medicine · 1 drug in this class